About TeloiX

What TeloiX is

TeloiX is a reference site built around a mechanism–intervention–study graph for telomere biology (telomere attrition, telomerase, shelterin, the Hayflick limit, ALT) and the interventions claimed to lengthen telomeres or activate telomerase. It is deliberately narrow: a small number of landmark interventions and studies, each fully sourced and honestly qualified, rather than a broad advice article. It reports what each study actually measured — telomere length? telomerase activity? a clinical outcome? — in which population. Telomere-driven replicative senescence is cross-referenced to the senesiq cluster, not duplicated.

The central honesty facts

No telomere intervention has a healthy-aging human lifespan randomized controlled trial. The human evidence here is real but qualified: a telomere-length biomarker RCT (TA-65), clinical outcomes in a rare telomere disease (danazol, nandrolone), and a small cancer-cohort pilot (Ornish). Beyond that, two truths govern every page: telomere length is a contested aging biomarker (longer is not simply healthier), and telomerase activation is not risk-free — the only FDA-approved telomerase drug, imetelstat (2024), inhibits telomerase to treat cancer, the opposite direction from anti-aging "activation."

Commercial conflict-of-interest note

The most-cited human "telomerase activator" data on this site — the TA-65 telomere-length RCT (Salvador 2016) and the earlier immune study (Harley 2011) — were produced by authors with a direct commercial interest in the product. TA-65 is sold by T.A. Sciences; Calvin Harley (a TA-65 co-inventor and long-time commercial proponent) and other T.A. Sciences–affiliated authors appear on those papers. This does not by itself invalidate the results, but it is a material conflict of interest that a reader weighing a supplement marketed on telomere claims must know. TeloiX has no commercial relationship with T.A. Sciences or any product mentioned.

Publisher / editorial identity

Nabus Research is the editorial owner and publisher. This site does not attribute content to any named individual author or reviewer; no person is fabricated for E-E-A-T purposes. When a named, verifiable human reviewer is assigned to a page in a future revision, that attribution will be added — and not before.

Editorial review process

Every intervention page on this site (schema.org MedicalWebPage) carries a visible “Reviewed by Nabus Research” byline with a lastReviewed date, matched by reviewedBy/lastReviewed structured data. This is an organizational editorial review — each page is checked against its data record, verification statuses, and the prohibited-claim-language pattern check at build time — not a claim of individual clinical review; see “Publisher / editorial identity” above for why no named reviewer is attributed yet.

Sourcing standard

Every study record carries five visible qualifiers: species/population; exposure, route and schedule; comparator and duration; endpoint and numeric result; and what the study did NOT establish. Every record carries a verification_status, and every trial/registry identifier a citation_status. Journal/volume/DOI were confirmed via Crossref and trial status via the ClinicalTrials.gov v2 API where an identifier was resolvable. An identifier that cannot be confirmed against the primary record is left empty and named as unconfirmed in the record itself — it is never presented as verified and never filled in from a secondary source. See the methodology page.

Monetization

One intervention page — TA-65 (cycloastragenol) — carries an affiliate link. The link points to an affiliate link to the material the trials used. No sponsored placements, no ads.txt, no advertiser input of any kind. Prescription and investigational compounds are never linked. The TA-65 page carries an open conflict-of-interest note about the trial authors, and it stays there. This is still a reference resource, not a shopping guide; see the affiliate disclosure.

Prohibited claim language

The editorial process blocks a fixed list of prohibited marketing phrases — for example, claims that lengthening telomeres turns back your biological clock, that a supplement is a telomerase ‘fountain of youth’, that telomerase activation is risk-free, or that any compound here has a proven human lifespan effect — via an automated pattern check run at build time. See generators/check_claim_patterns.py.

Licensing & data enquiries

The structured telomere evidence dataset behind this site is independently sourced. For dataset-licensing or research-data enquiries, use the form below. This is an inbound enquiry channel only: submitting it does not buy coverage, placement, or a change to any record, and no sponsored placements or advertising appear anywhere on this site. One intervention page — TA-65 (cycloastragenol) — carries an affiliate link.

Version history